Camber launches sirolimus oral solution
Sirolimus oral solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in certain patients.
Camber is introducing sirolimus oral solution.
The medication is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years, receiving renal transplants.
[Read more: Camber debuts generic Tarceva]
- Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
- Patients at high immunologic risk: use in combination with CsA and corticosteroids
Sirolimus oral solution 1 mg/ml is now available in a 60 ml bottle.